IMMX
Immix Biopharma, Inc.
$8.18
+2.12%
$559.0M
No data for this timeframe.
Vol
Market Cap$559.0M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders4 funds
Inst. Value$7.7M
Inst. Activity3 buys / 0 sells
SEC Reports1
Press Releases1
Recent Activity
May 22, 2026
other
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
<p align="center"><i>– Financing includes leading U.S. biotechnology institutional investors and mut
May 22, 2026
Insider
Adams Helen C. sold 6,250 shares
Director @ $0.00 ($0.00)
May 22, 2026
Insider
Marquet Magda sold 12,500 shares
Director @ $0.00 ($0.00)
May 22, 2026
Insider
CHANG NANCY T sold 12,500 shares
Director @ $0.00 ($0.00)
May 21, 2026
SEC
Immix Biopharma priced an underwritten offering of 16,778,524 shares at $8.94 per share, raising $150M in gross proceeds
8-K — Impact 7/10
Inst.
VANGUARD GROUP INC — ADD
1,095,814 shares ($5.7M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
258,600 shares ($1.4M)
May 21, 2026
Press
Immix Biopharma announced that all four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have conv
Impact 8/10
Price Targets
$18.46
+125.6% upside
Strong Buy
Current $8.18
Low $14.50
Median $20.00
High $22.78
5 analysts
$14.50
$22.78
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 22, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 30, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 30, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Mar 27, 2026 | Citizens | REITERATE | Market Outperform → Market Outperform |
| Mar 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.18 ▲ +11.0% | $-0.22 — $-0.15 | 17% YoY | 4 |
| Next Q | $-0.17 ▲ +15.7% | $-0.22 — $-0.14 | 27% YoY | 4 |
| Current FY | $-0.70 ▲ +9.4% | $-0.87 — $-0.57 | 22% YoY | 5 |
| Next FY | $-0.65 ▲ +11.0% | $-1.01 — $-0.08 | 7% YoY | 4 |
Latest Reports
BEARISH
8-K
7/10
Immix Biopharma priced an underwritten offering of 16,778,524 shares at $8.94 per share, raising $150M in gross proceeds
May 21, 2026
BULLISH
Press
8/10
Immix Biopharma announced that all four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have conv
May 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $5.7M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $1.4M | DOUBLED |
| MORGAN STANLEY | $662.2K | ADD |
| BANK OF AMERICA CORP | $84.00 | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 22, 2026 | Adams Helen | A | $0.00 |
| May 22, 2026 | Marquet Magda | A | $0.00 |
| May 22, 2026 | CHANG NANCY | A | $0.00 |
| May 22, 2026 | BUCHAN JANE | A | $0.00 |
| May 22, 2026 | Hsu Jason | A | $0.00 |
4 institutional holders with $7.7M total value (1,481,052 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,095,814 | $5.7M | 74.0% | ADD +50.1% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 258,600 | $1.4M | 17.5% | DOUBLED +1102.8% |
| 3 | MORGAN STANLEY | 126,622 | $662.2K | 8.5% | ADD +51.8% |
| 4 | BANK OF AMERICA CORP /DE/ | 16 | $84.00 | 0.0% | ADD +33.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 730,162 | 1,095,814 | +50.1% | $5.7M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 21,500 | 258,600 | +1102.8% | $1.4M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 12 | 16 | +33.3% | $84.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 21,500 | — | $44.9K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 13,972 | 1,940 | -86.1% | $4.1K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 139 | 12 | -91.4% | $25.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 82,292 | 124,919 | +51.8% | $258.6K | 2025-Q2 |
| UBS Group AG | ADD | 10,121 | 13,972 | +38.0% | $28.9K | 2025-Q2 |
| UBS Group AG | TRIM | 14,208 | 10,121 | -28.8% | $17.0K | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 12,400 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 6,146 | 14,208 | +131.2% | $31.3K | 2024-Q4 |
| MORGAN STANLEY | ADD | 58,457 | 84,313 | +44.2% | $125.6K | 2024-Q3 |
9 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 22, 2026 | Adams Helen C. | Director | A | 6,250 | $0.00 | $0.00 |
| May 22, 2026 | Marquet Magda | Director | A | 12,500 | $0.00 | $0.00 |
| May 22, 2026 | CHANG NANCY T | Director | A | 12,500 | $0.00 | $0.00 |
| May 22, 2026 | BUCHAN JANE | Director | A | 12,500 | $0.00 | $0.00 |
| May 22, 2026 | Hsu Jason | Director | A | 6,250 | $0.00 | $0.00 |
| May 22, 2026 | Morris Gabriel S | CFO, President | A | 500,000 | $0.00 | $0.00 |
| May 22, 2026 | Chudnovsky Yekaterina | Director | A | 12,500 | $0.00 | $0.00 |
| May 22, 2026 | CHANG NANCY T | Director | A | 6,250 | $0.00 | $0.00 |
| May 22, 2026 | Hsu Jason | Director | A | 12,500 | $0.00 | $0.00 |
| May 22, 2026 | Ng Carey | Director | A | 12,500 | $0.00 | $0.00 |
| May 22, 2026 | BUCHAN JANE | Director | A | 6,250 | $0.00 | $0.00 |
| May 22, 2026 | Ng Carey | Director | A | 6,250 | $0.00 | $0.00 |
| May 22, 2026 | Adams Helen C. | Director | A | 12,500 | $0.00 | $0.00 |
| May 22, 2026 | Rachman Ilya M | CEO and Chairman | A | 500,000 | $0.00 | $0.00 |
| May 22, 2026 | Chudnovsky Yekaterina | Director | A | 6,250 | $0.00 | $0.00 |
| May 22, 2026 | Marquet Magda | Director | A | 6,250 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$18.46 mean target
+125.6% upside
Strong Buy (1.50)
$14.50 Low
$22.78 High
| Metric | Value |
|---|---|
| Current Price | $8.18 |
| Target Low | $14.50 |
| Target Mean | $18.46 |
| Target Median | $20.00 |
| Target High | $22.78 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.18 | $-0.22 | $-0.15 | 17.1% | +11.0% | 3↑ 1↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.17 | $-0.22 | $-0.14 | 27.1% | +15.7% | 2↑ 1↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-0.70 | $-0.87 | $-0.57 | 21.6% | +9.4% | 3↑ 1↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-12-31 |
$-0.65 | $-1.01 | $-0.08 | 7.2% | +11.0% | 1↑ 2↓ | $0.1B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.182 | |
| 7d ago | $-0.200 | +0.018 |
| 30d ago | $-0.205 | +0.022 |
| 60d ago | $-0.170 | -0.012 |
| 90d ago | $-0.150 | -0.033 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 22, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 30, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 30, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 27, 2026 | Citizens | REITERATE | Market Outperform | Market Outperform |
| Mar 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Morgan Stanley | INITIATE | — | Overweight |
| Mar 9, 2026 | Citizens | INITIATE | — | Market Outperform |
| Feb 9, 2026 | Mizuho | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 22, 2026
other
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
<p align="center"><i>– Financing includes leading U.S. biotechnology institutional investors and mutual funds –</i></p>
May 21, 2026
other
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
<p align="justify">LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global lea
May 21, 2026
fda
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
<p align="center"><i>– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) –</i></p>
May 6, 2026
earnings_calendar
IMMX Q1 2026 Earnings Scheduled — 2026-05-06
Apr 9, 2026
other
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
<p>LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in r
Mar 30, 2026
earnings
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
<p align="center"><i>– Full enrollment of BLA-enabling trial complete, per prior guidance –<br></i><br><i>– Topline NEXICART-2 Results Expected Q3 202
Mar 23, 2026
earnings_calendar
IMMX Q4 2025 Earnings After Market Close — 2026-03-23
Mar 3, 2026
other
Immix Biopharma to Participate in Upcoming Investor Conferences
<p>LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in r